Balyasny Asset Management
UNCY icon

Balyasny Asset Management’s Unicycive Therapeutics UNCY Stock Holding History

Balyasny Asset Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-71,735
Closed -$1.51M – 2818
2023
Q1 		$1.51M Buy
+71,735
New +$715K ﹤0.01% 1567

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return

Balyasny Asset Management's UNCY Position: Q2 2023 in Review

Balyasny Asset Management sold out of Unicycive Therapeutics (UNCY) in Q2 2023, closing a stake of 71,735 shares — an estimated $1.51M sold.

Balyasny Asset Management first reported a position in UNCY in Q1 2023 and held it in 1 quarter. The position peaked at $1.51M in Q1 2023. 15 funds tracked by Wall St. Rank hold UNCY as of Q2 2023.

  • Balyasny Asset Management reported no remaining Unicycive Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 71,735 Unicycive Therapeutics shares in Q2 2023, an estimated $1.51M.
  • Balyasny Asset Management first reported a position in Unicycive Therapeutics in Q1 2023 and held it in 1 quarter.
  • Balyasny Asset Management's Unicycive Therapeutics position peaked at $1.51M in Q1 2023.
  • 15 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.